Designing animal models for evaluation of therapeutic and vaccine candidates for emerging and biodefence-related pathogens By Dr Colleen Jonsson and Dr Peter Silvera While a number of promising drug therapies and vaccines have been identified for safeguarding bioterrorism organisms and diseases, further development requires well characterised animal models for testing… Read More
The evolving world of drug discovery data integration in the pharmaceutical industry Dr David Sedlock The world of drug discovery has been impacted significantly by an ever evolving use of computer systems during the past 25 years with the greatest change occurring during the past 10 years or so as… Read More
Establishment of an open access compound management facility By David Camp This article covers the establishment of an open access compound management facility in Australia to stimulate applied, basic and translational biomedical research. The paradigm for probing biological processes and drug discovery via small molecules has changed significantly over the… Read More
Lean Thinking for Drug Discovery – Better Productivity for Pharma By Dr Edward W. Petrillo Success in drug discovery controls the success of the pharmaceutical enterprise. The molecular structure of every drug candidate, and the body of knowledge that will guide its use in the treatment of disease, are established… Read More
Sharing Risks and Rewards - Basis for a turnkey pharma-biotech alliance in osteoarthritis Dr Andre Hoekema In June 2006, Galapagos and GlaxoSmithKline’s Center of Excellence for External Drug Discovery (CEEDD) formed a multi-year worldwide alliance to discover and develop novel drugs for osteoarthritis. The focus of the alliance will be… Read More
The Role of Repositioning in Drug Discovery and Development By Dr Louis A. Tartaglia and Dr Lee E. Babiss The large number of drug candidate failures in recent years has been enormously costly for the pharmaceutical industry, but has also created the tremendous opportunity of repositioning these molecules into new… Read More
Innovative Partnerships in Neglected Disease Research - The Novartis Institute for Tropical Diseases By Prof Paul Herrling While the recent biomedical revolution has given rise to significant advances in medical treatment, many neglected diseases that are endemic in underdeveloped parts of the world remain unaddressed. Public-private partnerships like the Novartis… Read More
The Genome as a Tool for Drug Discovery and Development the Case for Embracing Complexity By Dr Kenneth C. Carter Conventional drug discovery and development is centred on a paradigm in which 'validated' targets are subjected to in vitro screens for the identification of new drug candidates. Molecular profiling using… Read More
Zebrafish: a versatile in vivo model for drug safety assessment Dr Wendy Alderton and Dr St phane Berghmans Safety pharmacology has become an integral part of non-clinical safety assessment for new chemical entities in the past two decades (1). The relative novelty of this discipline has granted it the flexibility… Read More
Ion Channel Drug Targets: Unlocking the potential By Dr Dayle S. Hogg, Dr Philip Boden, Dr Geoff Lawton and Dr Roland Z. Kozlowski A striking number of drugs targeting ion channels have reached blockbuster status, generating $ billion revenues. In spite of the historical success of ion channels as therapeutic… Read More
The Timetable of Invention and it's Relevance to Drug Discovery By Dr William Bains The most critical question to any investor in new technology should not be whether a technology will work. Technologies nearly always work in the end, providing they do not break fundamental laws of physics, and are… Read More
By Dr Alpheus Bingham It has been suggested that the blockbuster business model, which has been the key to big pharma success, is now broken and completely beyond repair. In a truly global and fast changing business world, is it time to examine alternatives to the classic monolithic risk structure… Read More
Silence For Health - Development of RNA interference based cancer therapy By Dr Ansgar Santel RNA interference (RNAi) has become an invaluable tool for biomedical research. It is already routinely used as an indispensable approach for gene function analysis in basic biological research and for target identification as well as… Read More
Share Share Tweet Email Understanding the strategic importance of BIOMARKERS for the discovery and early development phases Understanding the strategic importance of BIOMARKERS for the discovery and early development phases By Dr Orest Hurko Biomarkers have become an increasingly hot topic in the pharmaceutical industry. How much of this is… Read More
By Dr George G. Harrigan The potential of metabolomics, a systems approach to biochemical pathway analysis, to yield scientific and commercial benefits to healthcare and biotechnology enterprises is increasingly recognised. This article discusses current applications and future developments and places an emphasis on incorporation of metabolomics within all aspects of… Read More
Applying the semantic web to drug discovery and development By Dr Eric Neumann There is much happening in drug development these days: new target classes, increasing costs, new forms of high throughput screening, and the promise of personalised medicine. But of all the issues, the one that now takes centre… Read More